Your SlideShare is downloading. ×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Dermatological Drugs Market 2014-2024

2,085
views

Published on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website …

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1242/Dermatological-Drugs-Market-Forecast-2014-2024

Published in: Business, Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,085
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
99
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Dermatological Drugs Market Forecast 2014-2024 Future Prospects for Leading Companies ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  • 2. www.visiongain.com Contents 1. Executive Summary 1.1 Overview of Findings 1.2 Structure of the Report 1.3 Research and Analysis Methods 1.4 Scope of this Report 1.5 Glossary of Terms in this Report 2. Introduction to Dermatological Drugs 2.1 The Pharmaceutical Industry: a Very Brief Overview 2.2 An Overview of Dermatology 2.2.1 The Structure of the Skin, Hair and Nails 2.2.2 Hair and Nails 2.2.3 Sweat and Sebaceous Glands 2.2.4 Functions of the Skin 2.3 Common Skin Diseases 2.4 Acne: The Most Common Skin Disease 2.4.1 Acne: Epidemiology 2.4.2 Acne: Causes and Pathogenesis 2.4.3 Acne: Treatment 2.5 Dermatitis: Inflammation of the Skin 2.5.1 Atopic Dermatitis 2.5.2 Contact Dermatitis 2.5.3 Seborrhoeic Dermatitis 1. Executive Summary 2. Introduction to Dermatological Drugs
  • 3. www.visiongain.com Contents 2.5.4 Nummular Dermatitis 2.5.5 Perioral Dermatitis 2.6 Psoriasis: A Complex Multi-factorial Disease 2.7 Rosacea: Vascular Instability 2.8 Alopecia: Excessive Shedding of Hair 2.9 Skin Infections: A Serious Healthcare Threat 2.9.1 Bacterial Skin Infections 2.9.2 Fungal Skin Infections 2.9.3 Viral Skin Infections 2.10 Common Skin Treatments 2.10.1 Creams and Semisolid Emulsions 2.10.2 Ointments 2.10.3 Lotions 2.10.4 Solutions 2.10.5 Occlusive Therapy 2.10.6 Cleansing Agents 2.10.7 Powders and Hydrophilic Polymer 2.10.8 Anti-Infective Agents 2.10.9 Anti-Inflammatory Agents 2.11 Phases of Clinical Trials 2.12 Dermatological Drugs in This Report 3. Dermatological Drugs: World Market 2014-2024 3.1 The World Dermatological Drugs Market in 2012 and 2013 3. Dermatological Drugs: World Market 2014-2024
  • 4. www.visiongain.com Contents 3.1.1 Leading Dermatological Drugs 3.1.2 Leading Companies in the Dermatological Drugs Market 3.2 World Dermatological Drugs Market: Sales Forecast 2014-2024 3.3 Psoriasis Drugs Lead the World Dermatological Drugs Market 3.4 How Will Segmental Market Shares Change to 2024? 3.5 World Dermatological Drugs Market: Drivers and Restraints 2014-2024 3.6 Opportunities for Blockbuster Sales 4. Leading National Markets 2014-2024 4.1 Geographical Breakdown of the World Dermatological Drugs Market 4.2 World Dermatological Drugs Market: National Markets Forecast 2014-2024 4.2.1 How Will National Market Shares Change to 2024? 4.3 The US Dermatological Drugs Market 2014-2024 4.3.1 US Dermatological Drugs Market Forecast 2014-2024 4.3.2 US Dermatological Drugs Market: Trends and Developments 4.3.2.1 Affordable Care Act: Expanding Medicare Coverage 4.3.2.2 A US Biosimilars Market? 4.4 Japanese Dermatological Drugs Market 2014-2024 4.4.1 Japanese Dermatological Drugs Market Forecast 2014-2024 4.4.2 Japanese Dermatological Drugs Market: Trends and Developments 4.4.2.1 The Cost of Treatment in Japan 4.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform 4.5 Chinese Dermatological Drugs Market 2014-2024 4.5.1 Chinese Dermatological Drugs Market Forecast 2014-2024 4. Leading National Markets 2014-2024
  • 5. www.visiongain.com Contents 4.5.2 Chinese Dermatological Drugs Market: Trends and Developments 4.5.2.1 Expansion of Healthcare Coverage and Reimbursement 4.5.2.2 Rapid Advancement of Dermatology in China 4.5.2.3 Price Controls and the Anhui Model 4.6 EU5 Dermatological Drugs Market 2014-2024 4.6.1 German Dermatological Drugs Market Forecast 2014-2024 4.6.2 French Dermatological Drugs Market Forecast 2014-2024 4.6.3 UK Dermatological Drugs Market Forecast 2014-2024 4.6.4 Italian Dermatological Drugs Market Forecast 2014-2024 4.6.5 Spanish Dermatological Drugs Market Forecast 2014-2024 4.7 Indian Dermatological Drugs Market 2014-2024 4.7.1 Indian Dermatological Drugs Market Forecast 2014-2024 4.7.2 Indian Dermatological Drugs Market: Trends and Developments 4.7.2.1 Drug Prices Control Order 2013 4.7.2.2 Expansion of Healthcare Provision 4.8 Brazilian Dermatological Drugs Market 2014-2024 4.8.1 Brazilian Dermatological Drugs Market Forecast 2014-2024 4.8.2 Brazilian Dermatological Drugs Market: Trends and Developments 4.8.2.1 Increasing Access to Medicines 4.9 Russian Dermatological Drugs Market 2014-2024 4.9.1 Russian Dermatological Drugs Market Forecast 2014-2024 4.9.2 Russian Dermatological Drugs Market: Trends and Developments 4.9.2.1 Pharma2020, Healthcare and Industry Reform 4.10 Mexican Dermatological Drugs Market 2014-2024
  • 6. www.visiongain.com Contents 4.10.1 Mexican Dermatological Drugs Market Forecast 2014-2024 4.10.2 Mexican Dermatological Drugs Market: Trends and Developments 4.10.2.1 Seguro Popular: Mexican Healthcare Reform 4.10.2.2 International Interest in Mexico 5. Psoriasis Drugs Market 2014-2024 5.1 Drugs for Psoriasis: The Success of Biologics 5.2 Leading Products in the Psoriasis Drug Market in 2012 and 2013 5.3 Psoriasis Drugs: Trends and Developments 5.3.1 Biological Drugs: An Overview 5.3.1.1 Disadvantages of Biologics 5.4 Psoriasis Drugs: Market Forecast 2014-2024 5.5 Market Share of Leading Psoriasis Drugs to 2024 5.6 Humira (adalimumab, AbbVie) 5.6.1 Humira: Sales Forecast 2014-2024 5.6.2 Prospects for Biosimilar Humira 5.7 Enbrel (etanercept, Amgen/Pfizer) 5.7.1 Enbrel: Sales Forecast 2014-2024 5.7.2 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years 5.7.3 Competition from Other Drugs 5.7.4 Biosimilar Competition for Enbrel 5.8 Stelara (ustekinumab, Johnson & Johnson) 5.8.1 Stelara: Sales Forecast 2014-2024 5.8.2 Competition for Stelara in the Pipeline 5. Psoriasis Drugs Market 2014-2024
  • 7. www.visiongain.com Contents 5.9 Remicade (infliximab, Johnson & Johnson) 5.9.1 Remicade: Sales Forecast 2014-2024 5.10 Daivobet (betamethasone/calcipotriene, LEO Pharma) 5.10.1 Daivobet: Sales Forecast 2014-2024 5.10.2 LEO Pharma’s Life Cycle Management of Daivobet 5.10.3 Daivobet/Dovobet/Taclonex – Generic Competition 5.11 Soriatane (acitretin, GSK) 5.11.1 Soriatane: Sales Forecast 2014-2024 5.12 Psoriasis Drugs Market: Summary 6. Skin Infection Drugs Market 2014-2024 6.1 Skin Infection Drugs: A Growing Submarket 6.2 Leading Products in the Skin Infections Drug Market in 2012 and 2013 6.3 Skin Infection Drugs: Market Forecast 2014-2024 6.4 Market Share of Leading Skin Infection Drugs to 2024 6.5 Cubicin (daptomycin, Cubist Pharmaceuticals) 6.5.1 Cubicin: Sales Forecast 2014-2024 6.5.2 Cubicin Lifecycle Management Strategies 6.5.3 Generic Competition for Cubicin 6.6 Zyvox (linezolid, Pfizer) 6.6.1 Zyvox: Sales Forecast 2014-2024 6.6.2 Tedizolid Threatens Zyvox Market Share 6.7 Valtrex (valaciclovir, GSK) 6.7.1 Valtrex: Sales Forecast 2014-2024 6. Skin Infection Drugs Market 2014-2024
  • 8. www.visiongain.com Contents 6.8 Canesten (clotrimazole, Bayer) 6.8.1 Canesten: Sales Forecast 2014-2024 6.9 Zovirax (aciclovir, Valeant/GSK) 6.9.1 Zovirax: Sales Forecast 2014-2024 6.9.2 Valeant Acquires Zovirax in US and Canada 6.9.3 Mylan’s Generic Zovirax and Actavis’s Authorised Generic 6.10 Bactroban (mupirocin, GSK) 6.10.1 Bactroban: Sales Forecast 2014-2024 6.11 Lamisil (terbinafine, Novartis) 6.11.1 Lamisil: Sales Forecast 2014-2024 6.11.2 Lamisil Sales Affected by Novartis Manufacturing Problems 6.12 Skin Infection Drugs Market: Summary 7. Acne Drugs Market 2014-2024 7.1 Drugs for Acne: A Highly Fragmented Market 7.2 Leading Products in the Acne Drug Market in 2012 and 2013 7.3 Acne Drugs: Trends and Developments 7.3.1 Combination Treatments for Acne 7.3.2 Oral Contraceptives in Treating Acne 7.3.3 Generic Competition in the Acne Drugs Market 7.4 Acne Drugs: Market Forecast 2014-2024 7.5 Market Share of Leading Acne Drugs to 2024 7.6 Solodyn (minocycline, Valeant) 7.6.1 Solodyn: Sales Forecast 2014-2024 7. Acne Drugs Market 2014-2024
  • 9. www.visiongain.com Contents 7.6.2 Antitrust Action over Solodyn Pay-For-Delay Deals 7.6.3 Impax and Medicis Collaborating on Advanced Solodyn 7.6.4 Medicis and Lupin Settle 7.7 Claravis (isotretinoin, Teva) 7.7.1 Claravis: Sales Forecast 2014-2024 7.8 Epiduo (adapalene/benzoyl peroxide, Galderma) 7.8.1 Epiduo: Sales Forecast 2014-2024 7.8.2 Galderma and Par Pharmaceutical Settle over Generic Epiduo 7.8.3 Epiduo Approved for Patients Aged 9-11 Years 7.9 Differin (adapalene, Galderma) 7.9.1 Differin: Sales Forecast 2014-2024 7.9.2 Federal Circuit Court Invalidates Differin Patents 7.10 Duac (clindamycin/benzoyl peroxide, GSK) 7.10.1 Duac: Sales Forecast 2014-2024 7.11 Aczone (dapsone, Allergan) 7.11.1 Aczone: Sales Forecast 2014-2024 7.12 Amnesteem (isotretinoin, Mylan) 7.12.1 Amnesteem: Sales Forecast 2014-2024 7.13 Doryx (doxycycline, Actavis) 7.13.1 Doryx: Sales Forecast 2014-2024 7.13.2 Warner Chilcott’s Lifecycle Management Strategies 7.13.3 Generic Competition for Doryx 7.14 Ziana (clindamycin/tretinoin, Valeant) 7.14.1 Ziana: Sales Forecast 2014-2024
  • 10. www.visiongain.com Contents 7.14.2 Actavis to Launch Generic Ziana in 2016 7.15 Acanya (clindamycin/benzoyl peroxide, Dow/Valeant) 7.15.1 Acanya: Sales Forecast 2014-2024 7.15.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA 7.15.3 Dow/Valeant File Suit Against Perrigo’s ANDA 7.16 Absorica/Epuris (CIP-isotretinoin, Cipher) 7.16.1 Absorica/Epuris: Sales Forecast 2014-2024 7.17 Other Products 7.17.1 Diane (cyproterone/ethinyl estradiol, Bayer) 7.17.2 Veltin (tretinoin/clindamycin, GSK) 7.18 Acne Drugs Market: Summary 8. Dermatitis Drugs Market 2014-2024 8.1 Dermatitis Drugs: High Generic Penetration 8.2 Leading Products in the Dermatitis Drug Market in 2012 and 2013 8.3 Dermatitis Drugs: Market Forecast 2014-2024 8.4 Market Share of Leading Dermatitis Drugs to 2024 8.5 Bepanthen (dexpanthenol, Bayer) 8.5.1 Bepanthen: Sales Forecast 2014-2024 8.6 Protopic (tacrolimus, Astellas Pharma/Roche) 8.6.1 Protopic: Sales Forecast 2014-2024 8.6.2 Protopic Benefits from Expanded Indication 8.6.3 Generic Competition for Protopic 8.7 Elocon (mometasone, Merck & Co.) 8. Dermatitis Drugs Market 2014-2024
  • 11. www.visiongain.com Contents 8.7.1 Elocon: Sales Forecast 2014-2024 8.8 Elidel (pimecrolimus, Meda/Valeant) 8.8.1 Elidel: Sales Forecast 2014-2024 8.9 Dermatitis Drugs Market: Summary 9. Leading Companies in the Dermatological Drugs Market 9.1 Galderma 9.1.1 Galderma: Dermatological Drugs Product Portfolio 9.1.2 Galderma: Sales Forecast 2014-2024 9.1.3 Galderma: Products in Development 9.1.3.1 NVC-422 (auriclosene) for Rosacea 9.1.4 Galderma: Recent Developments 9.1.4.1 Nestlé Acquires 100% of Galderma 9.1.4.2 Galderma Laboratories Restructuring 9.1.4.3 Mirvaso Launched for Rosacea 9.2 Johnson & Johnson 9.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio 9.2.2 Johnson & Johnson: Sales Forecast 2014-2024 9.2.3 Johnson & Johnson: Products in Development 9.3 AbbVie 9.3.1 AbbVie: Dermatological Drugs Product Portfolio 9.3.2 AbbVie: Sales Forecast 2014-2024 9.3.3 AbbVie: Products in Development 9.3.3.1 BT-061 (tregalizumab) for Psoriasis 9. Leading Companies in the Dermatological Drugs Market
  • 12. www.visiongain.com Contents 9.4 GSK 9.4.1 GSK: Dermatological Drugs Product Portfolio 9.4.2 GSK: Sales Forecast 2014-2024 9.4.3 GSK: Products in Development 9.4.4 GSK: Recent Developments 9.4.4.1 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU 9.4.4.2 GSK’s China Corruption Probe 9.5 Pfizer 9.5.1 Pfizer: Dermatological Drugs Product Portfolio 9.5.2 Pfizer: Sales Forecast 2014-2024 9.5.3 Pfizer: Products in Development 9.6 LEO Pharma 9.6.1 LEO Pharma: Dermatological Drugs Product Portfolio 9.6.2 LEO Pharma: Sales Forecast 2014-2024 9.6.3 LEO Pharma: Products in Development 10. Dermatological Drugs Pipeline Analysis 2014-2024 10.1 New Technology in R&D Pipeline Activities 10.1.1 Reformulation 10.1.2 Combination Treatments 10.1.3 New Mechanisms and Drug Delivery Technologies 10.1.4 Potential Market Entrants 10.2 Psoriasis: Filed or Recently Launched 10.2.1 Cimzia (certolizumab, UCB) 10. Dermatological Drugs Pipeline Analysis 2014-2024
  • 13. www.visiongain.com Contents 10.2.2 Sorilux (calcipotriene foam, GSK) 10.3 Psoriasis: Phase 3 Pipeline 10.3.1 000-0551 Lotion (halobetasol, Therapeutics, Inc.) 10.3.2 AIN457 (secukinumab, Novartis) 10.3.3 AMG827 (brodalumab, AstraZeneca/Amgen) 10.3.4 CF101 (IB-MECA, Can-Fite BioPharma) 10.3.5 LAS41008 (dimethyl fumarate , Almirall) 10.3.6 LEO 90100 (LEO Pharma) 10.3.7 LY2439821 (ixekizumab, Eli Lilly) 10.3.8 MK-3222/SCH 900222 (tildrakizumab, Merck) 10.3.9 Otezla (apremilast, Celgene) 10.3.10 STF 115469 (calcipotriene foam, GSK) 10.3.11 Xeljanz (tofacitinib, Pfizer) 10.4 Psoriasis: Phase 2 Pipeline 10.4.1 AN2728 (PDE-4 inhibitor, Anacor Pharmaceuticals) 10.4.2 CNTO 1959 (guselkumab, MorphoSys/Janssen) 10.4.3 CT327 (TrkA inhibitor, Creabilis Therapeutics) 10.4.4 ASP015K (JAK inhibitor, Janssen/Astellas) 10.4.5 Jakavi/Jakafi (ruxolitinib, Incyte/Novartis) 10.4.6 LY3009104 (baricitinib, Incyte/Eli Lilly) 10.4.7 PH-10 (Rose bengal, Provectus Biopharmaceuticals) 10.5 Psoriasis: Phase 1 and Preclinical Pipeline 10.6 Psoriasis: Recently Terminated Drugs 10.6.1 Ozespa (briakinumab, Abbott)
  • 14. www.visiongain.com Contents 10.6.2 AEB071 (sotrastaurin, Novartis) 10.6.3 Voclera (voclosporin, Aurinia) 10.7 Skin Infections: Phase 3 Pipeline 10.7.1 AN2690 (tavaborole, Anacor) 10.7.2 Dalvance (dalbavancin, Durata Therapeutics) 10.7.3 Delafloxacin (delafloxacin, Melinta Pharmaceuticals) 10.7.4 Jublia (efinaconazole, Valeant) 10.7.5 NB-001 (NanoBio Corporation) 10.7.6 Nuvocid (oritavancin, The Medicines Company) 10.7.7 TR-701 (tedizolid, Cubist) 10.7.8 Luliconazole (Topica Pharmaceuticals) 10.8 Skin Infections: Phase 2 Pipeline 10.9 Skin Infections: Phase 1 and Preclinical Pipeline 10.10 Acne: Phase 3 Pipeline 10.10.1 Duac low dose (clindamycin/benzoyl peroxide, GSK) 10.10.2 Visonac (photodynamic therapy, Photocure) 10.11 Acne: Phase 2 Pipeline 10.12 Acne: Phase 1 and Preclinical Pipeline 10.12.1 Acne Vaccine – A Treatment for the Future? 10.13 Dermatitis: Phase 3 Pipeline 10.13.1 Toctino (alitretinoin, GSK) 10.13.2 Dermadexin and Pruridexin (P3CGM, Astion Pharma) 10.13.3 Dexeryl Cream (glycerol/paraffin emollient, Pierre Fabre) 10.13.4 Soriatane (acitretin, InnovaDerm/Tribute Pharmaceuticals)
  • 15. www.visiongain.com Contents 10.14 Dermatitis: Phase 2 Pipeline 10.14.1 REGN668/SAR231893 (dupilumab, Regeneron/Sanofi) 10.15 Dermatitis: Phase 1 and Preclinical Pipeline 10.16 Other Dermatological Drugs: Filed or Recently Launched 10.16.1 Actikerall (fluorouracil/salicylic acid, Almirall) 10.16.2 Ameluz (5-ALA photodynamic therapy, Biofrontera) 10.16.3 Mirvaso (brimonidine, Galderma) 10.16.4 Picato (ingenol mebutate, LEO Pharma) 10.16.5 Xolair (omalizumab, Novartis/Roche) 10.17 Other Dermatological Drugs: Phase 3 Pipeline 10.17.1 Atralin (tretinoin, Valeant) 10.17.2 BMS-936558 (nivolumab, Bristol-Myers Squibb) 10.17.3 CD5024 (ivermectin, Galderma) 10.17.4 Latisse (bimatoprost, Allergan) 10.17.5 LEE011, LGX818 and MEK162 (Novartis) 10.17.6 MK-3475 (lambrolizumab, Merck) 10.17.7 Oleogel-S10 (triterpene extract, Birken) 10.17.8 PV-10 (Rose bengal, Provectus Pharmaceuticals) 10.17.9 SR-T100 gel (Solanum incanum extract, G&E Herbal Biotechnology) 10.17.10 TVEC (talimogene laherparepvec, Amgen) 10.18 Other Dermatological Drugs: Phase 2 Pipeline 10.19 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
  • 16. www.visiongain.com Contents 11. Qualitative Analysis of the Dermatological Drugs Market 2014-2024 11.1 SWOT Analysis of the Dermatological Drugs Market 11.2 Strengths 11.2.1 A Strong R&D Pipeline 11.2.2 High Unmet Clinical Need 11.2.3 Strong Industry-Physician Relationships 11.3 Weaknesses 11.3.1 Patient Adherence to Treatment 11.3.2 Limited Efficacy and Adverse Effects 11.3.3 Patent Expiry and Generic Competition 11.4 Opportunities 11.4.1 Growth Areas: Skin Infections, Onychomycosis and Melanoma 11.4.2 Consolidation in the Dermatology Market? 11.4.3 Personalised Dermatology: Technological Advances in Genomics 11.4.4 Advances in Topical Drug Delivery Methods 11.5 Threats 11.5.1 Increasing R&D Costs 11.5.2 Uncertain Reimbursement 11.5.3 Downward Pressures on Drug Prices 11.6 Porter’s Five Forces Analysis of the Dermatological Drugs Market 11.6.1 Rivalry Among Competitors [Medium] 11.6.2 Threat of New Entrants [High] 11.6.3 Power of Suppliers [Low] 11.6.4 Power of Buyers [Medium] 11. Qualitative Analysis of the Dermatological Drugs Market 2014-
  • 17. www.visiongain.com Contents 11.6.5 Threat of Substitutes [Medium] 12. Research Interviews 12.1 Interview with Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA 12.1.1 Provectus’ Pipeline: PV-10 and PH-10 12.1.2 The Dermatological Drugs Market 12.2 Interview with Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern- Öschelbronn, Germany 12.2.1 Birken’s Pipeline: Oleogel S-10 12.2.2 The Dermatological Drugs Market 12.3 Interview with Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA 12.3.1 Psoriasis: Unmet Patent Needs 12.3.2 Leading Dermatology Markets 12.3.3 Patient Adherence is Crucial 12.3.4 The Future of Biological Drug Treatments 12.3.5 Technological and Pipeline Developments 12.3.6 Challenges for Dermatologic Treatments 12.4 Interview with Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG, Leverkusen, Germany 12.4.1 Current State of the Dermatological Drug Market 12.4.2 Biofrontera and Dermatologic Drugs 12.4.3 Future Prospects for the Dermatological Drug Market 12.4.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers 12. Research Interviews
  • 18. www.visiongain.com Contents 12.4.5 Challenges Facing the Dermatologic Drug Market 12.4.6 Thoughts on Biologics, Small Molecule and Combination Therapies 13. Conclusions 13.1 The World Dermatological Drugs Market in 2012 and 2013 13.1.1 Current Leading Dermatological Drugs Segments 13.1.2 Leading Dermatological Drugs Products 13.1.3 Leading Dermatological Drugs Companies 13.1.4 Leading National Markets 13.2 World Dermatological Drugs Market Forecast 2014-2024 13.3 The Future of the Dermatological Drugs Market? 13. Conclusions
  • 19. www.visiongain.com Page 98 Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies Table 4.12 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024 2012 2013 2014 2015 2016 2017 2018 Spain ($m) 452 487 521 551 570 592 602 Annual Growth Rate (%) 7.9 7.1 5.6 3.5 3.9 1.6 CAGR (%, 2012-2018) 4.9 2018 2019 2020 2021 2022 2023 2024 Spain ($m) 602 617 633 647 666 682 695 Annual Growth Rate (%) 1.6 2.5 2.5 2.4 2.8 2.4 2.0 CAGR (%, 2018-2024) 2.4 CAGR (%, 2012-2024) 3.7 Figure 4.15 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024 Visiongain predicts that the Spanish market will grow with a CAGR of 4.9% over 2012-2018 to reach $602m in 2018. As in other EU countries, growth in healthcare spending will be limited by slow economic growth. In 2011, a fall in total spending was noted by the Spanish health ministry. The market will be restrained by recent financial problems and laws introduced by the Spanish government mean that the pharmaceutical market will be increasingly supplied with generic drugs; therefore making a challenging R&D environment over the forecast period. However, the need for new dermatologic drug treatments, such as those for treating skin cancer and skin and skin 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 0 100 200 300 400 500 600 700 800 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014
  • 20. www.visiongain.com Page 123 Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies The annual cost of treatment with Stelara is reportedly $18,200 for a low dose or $33,600 for a high dose. This is apparently more expensive than $14,543 Enbrel and $16,978 Humira, reports also indicate. The drug’s high revenue is affected by this high cost; in 2012, sales of Stelara generated $1,025m. 5.8.1 Stelara: Sales Forecast 2014-2024 Table 5.7 and Figure 5.7 show visiongain’s estimates of Stelara revenues in psoriasis and psoriatic arthritis over 2012-2024. Table 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), CAGR (%), 2012-2024 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Stelara ($m) 1,025 1,504 1,835 2,055 2,240 2,419 2,540 2,667 2,774 2,829 2,914 2,943 1,913 Annual Growth Rate (%) 46.7 22.0 12.0 9.0 8.0 5.0 5.0 4.0 2.0 3.0 1.0 -35.0 CAGR (%, 2012-2018 and 2018-2024) 16.3 -4.6 CAGR (%, 2012-2024) 5.3 Figure 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), 2012-2024 In 2012, Johnson & Johnson reported Stelara revenues of $1,025m, representing 16.9% of the psoriasis drugs market. This increased in 2013 to $1,504m, up 46.7% on 2012. Growth was due to -40.0 -30.0 -20.0 -10.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 0 500 1,000 1,500 2,000 2,500 3,000 3,500 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014
  • 21. www.visiongain.com Page 200 Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies The company reports revenues from its Dermatology business segment, which includes Bactroban and Duac (and presumably Soriatane) but excludes Valtrex and Zovirax. GSK also markets drugs for treating melanoma, notably Tafinlar and Mekinist, though these have not been considered part of GSK’s dermatology revenues. 9.4.2 GSK: Sales Forecast 2014-2024 Table 9.8 and Figure 9.4 show visiongain’s estimates of GSK’s dermatological drugs revenues over 2012-2024. Table 9.8 GSK: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 GSK ($m) 1,888 1,682 1,544 1,497 1,468 1,450 1,439 1,435 1,416 1,401 1,390 1,379 1,370 Annual Growth Rate (%) -10.9 -8.2 -3.0 -2.0 -1.2 -0.7 -0.3 -1.3 -1.0 -0.8 -0.7 -0.7 CAGR (%, 2012-2018 and 2018-2024) -4.4 -0.8 CAGR (%, 2012-2024) -2.6 Figure 9.4 GSK: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024 Visiongain’s sales forecast for GSK includes GSK’s reported Dermatology revenues, as well as sales of Valtrex and GSK’s share of sales of Zovirax. We estimate that in 2012, GSK's -12.0 -10.0 -8.0 -6.0 -4.0 -2.0 0.0 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014